|
KR100464264B1
(ko)
*
|
2002-03-21 |
2005-01-03 |
주식회사 파나진 |
광분해 보호기를 갖는 신규한 pna 단량체
|
|
KR20030084444A
(ko)
*
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
|
EP1722792A1
(de)
*
|
2004-03-03 |
2006-11-22 |
Boehringer Ingelheim International GmbH |
Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
|
|
WO2006086667A2
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
EP1904079A4
(de)
|
2005-06-02 |
2009-10-21 |
Advandx Inc |
Peptid-nukleinsäure-sonden zur untersuchung von mikroorganismen
|
|
KR101072899B1
(ko)
|
2008-01-21 |
2011-10-17 |
주식회사 파나진 |
아미노산 스페이서가 결합된 펩티드 핵산의 합성 및 그의응용
|
|
WO2009136693A1
(en)
*
|
2008-05-06 |
2009-11-12 |
Panagene Inc. |
Peptide nucleic acid probes, kits and methods for expression profiling of micrornas
|
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2010141511A2
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
|
AU2010319314C1
(en)
|
2009-11-13 |
2016-09-01 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
WO2011064552A1
(en)
|
2009-11-30 |
2011-06-03 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
|
US9068185B2
(en)
|
2010-03-12 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
CA2797093C
(en)
|
2010-04-26 |
2019-10-29 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
|
CA2797362C
(en)
|
2010-04-27 |
2020-12-08 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
|
WO2011139853A2
(en)
|
2010-04-28 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
|
US8986680B2
(en)
|
2010-04-29 |
2015-03-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
|
|
EP2563383B1
(de)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
|
|
CA2797977C
(en)
|
2010-05-03 |
2019-08-20 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
|
|
CN103140233B
(zh)
|
2010-05-03 |
2017-04-05 |
Atyr 医药公司 |
与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
|
WO2011139986A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
|
EP2566499B1
(de)
|
2010-05-04 |
2017-01-25 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
|
|
EP3023496B1
(de)
|
2010-05-13 |
2020-07-29 |
Sarepta Therapeutics, Inc. |
Verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
|
|
CA2799197C
(en)
|
2010-05-14 |
2019-10-29 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
|
US9034598B2
(en)
|
2010-05-17 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
|
|
AU2011258106B2
(en)
|
2010-05-27 |
2017-02-23 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
|
|
JP6116479B2
(ja)
|
2010-07-12 |
2017-04-19 |
エータイアー ファーマ, インコーポレイテッド |
グリシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
US8791121B2
(en)
|
2010-08-12 |
2014-07-29 |
New York University |
Oligooxopiperazines and methods of making and using them
|
|
JP5964304B2
(ja)
|
2010-08-25 |
2016-08-03 |
エータイアー ファーマ, インコーポレイテッド |
チロシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
CA2839593A1
(en)
|
2011-07-15 |
2013-01-24 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
|
KR101303699B1
(ko)
|
2011-07-20 |
2013-09-09 |
대한민국 |
Pna 칩을 이용한 다종 식중독균 검출 방법
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
WO2013086444A2
(en)
|
2011-12-08 |
2013-06-13 |
Sarepta Therapeutics, Inc. |
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
|
|
WO2013119845A1
(en)
|
2012-02-07 |
2013-08-15 |
Vibrant Holdings, Llc |
Substrates, peptide arrays, and methods
|
|
US10006909B2
(en)
|
2012-09-28 |
2018-06-26 |
Vibrant Holdings, Llc |
Methods, systems, and arrays for biomolecular analysis
|
|
US9695153B2
(en)
|
2013-01-19 |
2017-07-04 |
New York University |
Oligooxopiperazines for p53 reactivation
|
|
AU2014317961B2
(en)
|
2013-09-05 |
2020-07-30 |
Murdoch University |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
KR101830700B1
(ko)
|
2013-11-11 |
2018-02-21 |
주식회사 파나진 |
클램핑 프로브 및 검출 프로브를 이용한 다중 표적핵산 검출방법
|
|
WO2015160914A1
(en)
|
2014-04-15 |
2015-10-22 |
New York University |
OXOPIPERAZINE HELIX MIMETICS AS INHIBITORS OF THE p53-MDM2 INTERACTION
|
|
KR101951172B1
(ko)
|
2014-11-07 |
2019-02-22 |
주식회사 파나진 |
인유두종바이러스의 유전자형 검출을 위한 ρνα 프로브, 키트 및 방법
|
|
EP3221445B1
(de)
|
2014-11-20 |
2021-07-14 |
The Regents of The University of California |
Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
US10849917B2
(en)
|
2015-06-01 |
2020-12-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type VII collagen
|
|
MX2018002090A
(es)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
|
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス, インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
|
JP7027311B2
(ja)
|
2015-11-16 |
2022-03-01 |
オリックス ファーマシューティカルズ,インコーポレーテッド |
MyD88又はTLR3を標的とするRNA複合体を使用した加齢黄斑変性の治療
|
|
WO2017134525A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1
|
|
JP7049262B2
(ja)
|
2016-04-11 |
2022-04-06 |
オリックス ファーマシューティカルズ,インコーポレーテッド |
結合組織成長因子を標的とするrna複合体を用いた特発性肺胞線維症の治療
|
|
US11060089B2
(en)
|
2016-04-18 |
2021-07-13 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
JP7042255B2
(ja)
|
2016-04-29 |
2022-03-25 |
サレプタ セラピューティクス, インコーポレイテッド |
ヒトlmnaを標的にするオリゴヌクレオチド類縁体
|
|
KR20190024977A
(ko)
|
2016-06-30 |
2019-03-08 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머
|
|
WO2018017814A1
(en)
|
2016-07-20 |
2018-01-25 |
President And Fellows Of Harvard College |
Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
|
|
US11202818B2
(en)
|
2016-09-14 |
2021-12-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulating erythropoiesis
|
|
WO2018112032A1
(en)
|
2016-12-13 |
2018-06-21 |
President And Fellows Of Harvard College |
Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
|
|
PT4122497T
(pt)
|
2016-12-19 |
2024-06-12 |
Sarepta Therapeutics Inc |
Conjugados oligoméricos de salto de exão para a distrofia muscular
|
|
NZ755416A
(en)
|
2016-12-19 |
2023-05-26 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
ES3051834T3
(en)
|
2016-12-19 |
2025-12-30 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
ES2994451T3
(en)
|
2017-04-20 |
2025-01-24 |
Atyr Pharma Inc |
Compositions for treating lung inflammation
|
|
WO2018218250A2
(en)
|
2017-05-26 |
2018-11-29 |
Vibrant Holdings, Llc |
Photoactive compounds and methods for biomolecule detection and sequencing
|
|
US10421728B2
(en)
|
2017-06-08 |
2019-09-24 |
Amrita Vishwa Vidyapeetham |
Peptide nucleic acid monomer and a preparation method
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3687519A1
(de)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Kombinationstherapien zur behandlung von muskeldystrophie
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
|
EP3790985B1
(de)
|
2018-05-09 |
2026-04-15 |
Vibrant Holdings, LLC |
Verfahren zur synthese eines polynukleotidarrays unter verwendung von fotootaktivierten mitteln
|
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
EP4219717A3
(de)
|
2018-06-13 |
2023-12-20 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
US11273137B2
(en)
|
2018-09-04 |
2022-03-15 |
Board Of Trustees Of Michigan State University |
Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
|
|
BR112021011018A2
(pt)
|
2018-12-13 |
2021-08-31 |
Sarepta Therapeutics, Inc. |
Conjugados de oligômero para exon skipping para distrofia muscular
|
|
CA3132199A1
(en)
|
2019-03-12 |
2020-09-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
US20220226269A1
(en)
|
2019-06-12 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
|
|
JP7837276B2
(ja)
|
2020-03-04 |
2026-03-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
免疫療法に対する腫瘍細胞の感作のための方法及び組成物
|
|
WO2021242826A1
(en)
|
2020-05-27 |
2021-12-02 |
The Regents Of The University Of California |
Compositions and methods for transdifferentiating cells
|
|
WO2022056454A2
(en)
|
2020-09-14 |
2022-03-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating hpv-positive cancers
|
|
IL301306A
(en)
|
2020-09-16 |
2023-05-01 |
Harvard College |
Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
|
|
US20240425864A1
(en)
|
2021-09-30 |
2024-12-26 |
Sarepta Therapeutics, Inc. |
Antisense oligonucleotides having one or more abasic units
|
|
WO2023070086A1
(en)
|
2021-10-22 |
2023-04-27 |
Sarepta Therapeutics, Inc. |
Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
|
|
WO2023091704A1
(en)
|
2021-11-18 |
2023-05-25 |
Circularis Biotechnologies, Inc. |
Compositions and methods for production of circular nucleic acid molecules
|
|
US20250230412A1
(en)
|
2022-02-01 |
2025-07-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
|
|
EP4590311A2
(de)
|
2022-09-21 |
2025-07-30 |
Sarepta Therapeutics, Inc. |
Dmd-antisense-oligonukleotid-vermittelte exon-skipping-effizienz
|
|
AU2023371614A1
(en)
|
2022-11-04 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
US20260167661A1
(en)
|
2022-11-14 |
2026-06-18 |
BioNTech SE |
Rna capping efficiency assay
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
EP4702144A1
(de)
|
2023-04-27 |
2026-03-04 |
Sarepta Therapeutics, Inc. |
Antisense-oligomere zur behandlung von chronischer nierenerkrankung
|
|
WO2024231285A1
(en)
|
2023-05-05 |
2024-11-14 |
BioNTech SE |
Method of analysing contaminants in rna products by ion-pair chromatography
|
|
WO2025085810A2
(en)
|
2023-10-18 |
2025-04-24 |
Sarepta Therapeutics, Inc. |
Antisense oligomers for treatment of centronuclear myopathies
|